Boston Scientific (BSX) Stock Forecast & Price Target

$56.54 -0.27 (-0.48%)

As of 02:56 PM Eastern

Compare

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
3

Buy
24

Based on 27 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 3 have given a hold rating, 23 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$92.71
63.97% Upside

According to the 27 analysts' twelve-month price targets for Boston Scientific, the average price target is $92.71. The highest price target for BSX is $128.00, while the lowest price target for BSX is $68.00. The average price target represents a forecasted upside of 63.97% from the current price of $56.54.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSX Analyst Ratings Over Time

Type	Current Forecast 5/20/25 to 5/20/26	1 Month Ago 4/20/25 to 4/20/26	3 Months Ago 2/19/25 to 2/19/26	1 Year Ago 5/20/24 to 5/20/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	23 Buy rating(s)	22 Buy rating(s)	20 Buy rating(s)	22 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$92.71	$102.82	$108.36	$114.74
Forecasted Upside	63.97% Upside	68.54% Upside	42.94% Upside	7.72% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Boston Scientific Stock vs. The Competition

Type	Boston Scientific	Medical Companies	Broader Market
Consensus Rating Score	2.93	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	63.27% Upside	1,742.60% Upside	17.78% Upside
News Sentiment Rating	Positive News See Recent BSX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/19/2026	Robert W. Baird 3 of 5 stars	David Rescott 3 of 5 stars	Lower Target	Outperform	$78.00 ➝ $75.00	+34.26%
5/18/2026	Needham & Company LLC 4 of 5 stars	Mike Matson 2 of 5 stars	Reiterated Rating	Buy	$77.00	+39.12%
5/18/2026	Bank of America 4 of 5 stars	Bob Hopkins Not Rated	Lower Target	Buy	$105.00 ➝ $68.00	+22.86%
5/18/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$80.00	+46.21%
5/13/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C) ➝ Hold (C-)
4/29/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
4/23/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$105.00 ➝ $100.00	+52.10%
4/23/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$90.00	+36.61%
4/23/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$109.00 ➝ $71.00	+7.94%
4/23/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$94.00 ➝ $75.00	+15.47%
Get the Latest News and Ratings for BSX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.
4/23/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$124.00 ➝ $96.00	+47.81%
4/23/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$90.00 ➝ $85.00	+30.87%
4/22/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$87.00 ➝ $84.00	+29.33%
4/22/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$110.00 ➝ $100.00	+53.96%
4/21/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$90.00 ➝ $85.00	+39.34%
4/13/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$115.00 ➝ $90.00	+45.05%
4/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$94.00 ➝ $87.00	+40.78%
3/30/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Outperform	$97.00 ➝ $88.00	+27.14%
3/17/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$120.00 ➝ $105.00	+46.50%
2/26/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
2/6/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$112.00	+43.53%
2/5/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$135.00 ➝ $100.00	+27.61%
2/5/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$112.00 ➝ $96.00	+24.15%
2/5/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$130.00 ➝ $118.00	+56.29%
2/2/2026	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$115.00	+24.35%
2/2/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$115.00 ➝ $100.00	+7.53%
10/3/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
10/1/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$127.00 ➝ $128.00	+31.21%
2/3/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$95.00 ➝ $115.00	+11.65%
1/10/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$108.00	+12.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:41 PM ET.

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 15, 2026. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

The current stock price is around $64, which is significantly lower than its 52-week high of $109.50, presenting a potential buying opportunity for investors looking for value.
Boston Scientific Co. reported a strong quarterly revenue of $5.20 billion, exceeding analyst expectations, indicating robust business performance and growth potential.
The company has a solid return on equity of 19.17%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.
With a market capitalization of $78.80 billion, Boston Scientific Co. is well-positioned in the medical device industry, providing stability and growth prospects in a growing market.
The firm has a low debt-to-equity ratio of 0.42, indicating a conservative approach to leverage, which can reduce financial risk for investors.

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

Recent stockholder proposals, including one to allow shareholders to call special meetings with only 10% of shares, were not passed, which may indicate governance issues that could concern investors.
The company is currently facing litigation related to securities fraud allegations, which could pose financial risks and affect investor confidence.
Despite a strong quarterly performance, the stock has seen significant fluctuations, with a 52-week low of $52.81, suggesting volatility that may deter risk-averse investors.
Analysts have recently lowered their target prices for the stock, indicating a more cautious outlook on its future performance, which could signal potential challenges ahead.
The company’s PEG ratio of 0.99, while indicating potential for growth, also suggests that the stock may not be as undervalued as it appears, warranting caution for investors.

BSX Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $92.71, with a high forecast of $128.00 and a low forecast of $68.00.

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BSX shares.

According to analysts, Boston Scientific's stock has a predicted upside of 63.97% based on their 12-month stock forecasts.

Over the previous 90 days, Boston Scientific's stock had 2 downgrades and 1 upgrade by analysts.

Boston Scientific has been rated by research analysts at Argus, Bank of America, Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Daiwa Securities Group, Jefferies Financial Group, Mizuho, Needham & Company LLC, Oppenheimer, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Boston Scientific more than other "medical" companies. The consensus rating for Boston Scientific is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how BSX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Boston Scientific Recommendations

This page (NYSE:BSX) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BSX Analyst Ratings Over Time

BSX Analyst Recommendations By Month

BSX Price Targets by Month

Boston Scientific Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

Boston Scientific
Bull Case

Boston Scientific
Bear Case

BSX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Boston Scientific Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BSX Analyst Ratings Over Time

BSX Analyst Recommendations By Month

BSX Price Targets by Month

Boston Scientific Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

Boston Scientific Bull Case

Boston Scientific Bear Case

BSX Forecast - Frequently Asked Questions

What is Boston Scientific's forecast for 2026?

Should I buy or sell Boston Scientific stock right now?

Does Boston Scientific's stock price have much upside?

Has Boston Scientific been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Boston Scientific?

Do Wall Street analysts like Boston Scientific more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Boston Scientific Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Boston Scientific
Bull Case

Boston Scientific
Bear Case